Glenmark Expands U.S. Portfolio with Lacosamide
Glenmark launches bioequivalent Lacosamide Oral Solution, tapping a $57M U.S. market.
Glenmark Pharmaceuticals has announced the launch of Lacosamide Oral Solution, 10 mg/mL, a bioequivalent and therapeutically equivalent generic of Vimpat® Oral Solution by UCB, Inc. The product caters to a U.S. market valued at approximately $57 million annually as of October 2024.
Marc Kikuchi, President of Glenmark North America, emphasized the company's dedication to offering high-quality, affordable alternatives for patients. Glenmark's U.S. portfolio now includes 201 approved products, with 51 ANDAs pending FDA approval, as the company continues expanding through both internal development and external partnerships.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion